An investigation into the bradycardic effects of ST 155 [2-(2,6-dichlorophenylamino)-2-imidazoline HCl] in the anesthetized dog.
D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D002698:Chloralose / Q000494:pharmacology; D003864:Depression, Chemical; D004285:Dogs; D004837:Epinephrine / Q000494:pharmacology; D004983:Ethanolamines / Q000494:pharmacology; D005260:Female; D006145:Guanethidine / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects*; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D009020:Morphine / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D010424:Pentobarbital / Q000494:pharmacology; D010425:Pentolinium Tartrate / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D013997:Time Factors; D014628:Vagotomy
D004983:Ethanolamines; D007093:Imidazoles; D010879:Piperazines; D010643:Phenoxybenzamine; D000804:Angiotensin II; D002698:Chloralose; D009020:Morphine; D001285:Atropine; D010425:Pentolinium Tartrate; D011433:Propranolol; D010424:Pentobarbital; D009638:Norepinephrine; D004837:Epinephrine; D006145:Guanethidine